Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGN-3006 Safety Study in r/r AML and MDS
NCT03927261Phase 1Active, not recruiting
- Sponsor
- Precigen
- Start
- May 2019
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRGN-3006 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), sponsored by Precigen. Primary endpoints: Dose Limiting Toxicities and Treatment Emergent Adverse Events. Started May 2019; status: active, not recruiting.
02
Drugs
PRGN-3006
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT03927261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927261.